Immunologic characterization of 3 murine regimens of allergen-specific immunotherapy - 11/05/15
![](/templates/common/images/mail.png)
Abstract |
Background |
Allergen-specific immunotherapy (ASIT) is used to treat the symptoms of immediate type I hypersensitivity. The mechanisms driving establishment of allergen tolerance are not yet fully understood.
Objective |
The goal of this study was to develop and immunologically characterize 3 murine models of ASIT to simulate protocols currently used to treat patients with type I hypersensitivities.
Methods |
Ovalbumin (OVA)–sensitized mice were desensitized to OVA by means of repeated injections of OVA with a rapid, intermediate, or gradual protocol. After desensitization, mice were assessed for clinical sensitivity to OVA, and immunologic parameters were assessed.
Results |
Mice in all treatment protocols displayed decreased vascular permeability in response to OVA challenge after desensitization. Circulating OVA-specific IgE levels, as well as basophil activation in response to OVA stimulation and IgE cross-linking, were significantly decreased in all treatment groups. Intermediate and gradual protocols, but not rapid desensitization, suppressed splenocyte proliferation and production of IL-4, IL-5, and IFN-γ in response to OVA and polyclonal activation. Similarly, significant increases in IL-10 production, numbers of CD4+CD25+ forkhead box protein 3–positive regulatory T cells, and OVA-specific IgG1 antibody levels were only observed in mice undergoing prolonged ASIT regimens.
Conclusion |
Suppression of IgE-mediated activation is a common feature of all desensitization schedules. Induction of immunoregulatory networks requires prolonged desensitization schedules.
Le texte complet de cet article est disponible en PDF.Key words : Type I hypersensitivity, allergen-specific immunotherapy, mouse models, mast cells, basophils
Abbreviations used : ASIT, BrdU, FoxP3, OVA, PerCP, Treg
Plan
Supported by grant R01AI076522 from the National Institutes of Health/National Institute of Allergy and Infectious Diseases. |
|
Disclosure of potential conflict of interest: This study was funded with a grant from the National Institutes of Health/National Institute of Allergy and Infectious Diseases. The authors declare that they have no relevant conflicts of interest. |
Vol 135 - N° 5
P. 1341 - mai 2015 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?